NEW YORK, Jan. 15, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million.
Read the full report: https://www.reportlinker.com/p05721254
The report provides separate comprehensive analytics for the US, and Rest of World.
Annual estimates and forecasts are provided for the period 2018 through 2024. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 24 companies including many key and niche players such as:
- Adrenomed AG
- AM-Pharma B.V
- AMOMED Pharma GmbH
- Asahi Kasei Pharma America
- Endacea, Inc.
- InflaRx N.V.
Read the full report: https://www.reportlinker.com/p05721254
SEPSIS THERAPEUTICS MCP-6
MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW
Sepsis - A Prelude
New Treatment Protocols and New Definitions - Every Minute Counts!!
Aging Population: A Key Growth Driver for Sepsis Therapeutics
Table 1: Global Population Statistics for the 60+ Age Group (2017E) (includes corresponding Graph/Chart)
Table 2: Global Population by Age Group: Percentage-wise Breakdown for Different Age Groups for Years 2017, 2050, and 2100 (includes corresponding Graph/Chart)
Table 3: Global Population Statistics for the 60+ Age Group by Region (2017)
Table 4: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
Antibiotics and Vasopressors - The Current Standard of Care
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Current Anti-bacterial Drugs used in Sepsis
Current Antifungals used for Sepsis
Current Antivirals used for Sepsis
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
Argipressin Gains Approval for Septic Shock in 26 EU countries
Current & Future Analysis
Growth Drivers in a Nutshell
Market Restraints
3. MARKET DYNAMICS
A Market Characterized by High Unmet Medical Needs
Research Activity Enables Increased Awareness of Disease Pathogenesis
Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018
Select Sepsis Therapeutics under Phase III Clinical Trials: 2018
Novel Immune-Specific Modes of Action under Focus
Emphasizing on Endothelial Cell Function
HMGB1- A Potential Target for Future Therapies
Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management
Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients
Hydrocortisone Displays Potential in Septic Shock Treatment
Reduced Levels of Vitamin C Characterize Sepsis Patients
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models
World Sepsis Day Aims to Result in Improvement in Sepsis Management
NSAIDs Demonstrate Potential to Treat Sepsis
4. SEPSIS: AN OVERVIEW
Sepsis - A Major Life-Threatening Condition
Risk Profile
Most Vulnerable Groups: Newborns and the Elderly
A Growing Threat in Hospital Environment
Types of Sepsis
SIRS
Uncomplicated Sepsis
Severe Sepsis
Septic Shock
Septicemia
Bacteremia
Mortality Rates
Mortality Rate on a Decline
Hospital Re-Admission Rate Remains High
Symptoms to Identify Sepsis Patients
General Symptoms in Sepsis Patients
Symptoms Specific to Source of Infection
Biological Changes in Sepsis Patients
Organ Dysfunction Symptoms in Acute Cases
Common Sources of Sepsis
Stages of Sepsis' Progression
Treatment of Sepsis
General Approaches for Treatment of Severe Sepsis and Septic Shock
Overview of Traditional Treatment Approaches
Anti-microbials
Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
Vasopressors
Corticosteroids
Immunoglobulins
Anticoagulants
Neonatal Sepsis
5. COMPETITIVE LANDSCAPE
5.1 Focus on Select Global Players
Adrenomed AG (Germany)
AM-Pharma B.V. (Netherlands)
AMOMED Pharma GmbH (Austria)
Asahi Kasei Pharma America (USA)
Endacea, Inc. (USA)
InflaRx N.V. (Germany)
La Jolla Pharmaceutical Company (USA)
TaiRx, Inc. (USA)
5.2 Product Introductions/Approvals
Asahi Kasei Pharma Obtains Phase III Clinical Study Results for ART-123
Argipressin Receives Approval in 26 EU Countries
La Jolla Pharmaceutical Receives FDA Approval for Giapreza Injection
Sepsis Alliance Partners with La Jolla Pharmaceutical
6. GLOBAL MARKET PERSPECTIVE
Table 5: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region/Country - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
Table 6: World 5-Year Perspective for Sepsis Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2018, 2021, and 2024 (includes corresponding Graph/Chart)
7. REGIONAL MARKET PERSPECTIVE
7.1 The United States
A.Market Analysis
United States: The Largest Market for Sepsis Therapeutics
Alarming Incidence of Sepsis & Lack of Therapies
Table 7: Estimated Annual Incidence of Septic Shock in the US (2016 - 2022E) (includes corresponding Graph/Chart)
Aging Population: A Key Growth Factor
Table 8: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 9: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
B.Market Analytics
Table 10: The US Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
7.2 Rest of World
A.Market Analysis
Aging Population: Key Opportunity Indicator
Table 11: Aging Population in Canada (2015 & 2030):
Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 12: Aging Population in Europe by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
India
India: High Incidence of Neonatal Sepsis
Table 13: Estimated Incidence and Mortality Associated with AIDS, Breast Cancer, MI, and Sepsis in India (includes corresponding Graph/Chart)
Key Opportunity Indicator: Aging Population Statistics in Rest of World
Table 14: Aging Population in Asia-Pacific by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 15: Aging Population in Latin America by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 16: Aging Population in the Middle East by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 17: Aging Population in Africa by Region (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
B.Market Analytics
Table 18: Rest of World Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2
(includes corresponding Graph/Chart)
8. COMPANY PROFILES
Total Companies Profiled:
The United States (7) Canada (3) Japan (1) Europe (8) - France (1) - Germany (4) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (4) Middle East (1)
Read the full report: https://www.reportlinker.com/p05721254
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article